BG · Q4 2025 Earnings

Standalone Bunge → Viterra integration problem → "mildly dilutive" with synergies deferred → synergies pushed to 2027 with commercial synergies "still developing." The narrative arc across four quarters is a steady right-shift of when Viterra actually earns its keep. Three quarters ago Viterra was a closed deal with no quantified target; last quarter it was openly dilutive; this quarter management said "we don't have a lot baked into the forecast on a contribution in 26 for those either... they'll really be contributing a lot more as we get into 27." The signal: the FY2026 guide is essentially a standalone-Bunge earnings number with minimal Viterra accretion, and the synergy-driven re-rating thesis is now a 2027 story at the earliest.

The "weaker Q3" framing has hardened into a structurally back-half-weighted 2026 with Q1 called the worst quarter in years. Last quarter management telegraphed a 30/70 H1/H2 split for H2 2025; this quarter the same 30/70 split is applied to the entire year, layered with "even on the Q1, Q2, we're looking at a 35-65 type split... not much business done beyond Q1 right now. We're still pretty open on the balance of the year." That last clause matters: with eleven months of the year unhedged, the $7.50–$8.00 range is effectively a curve-derived placeholder, not a conviction call.

Policy uncertainty went from "tailwind we're waiting on" to explicitly excluded from the model. Last quarter management still framed early-2026 margin recovery as RVO-dependent; this quarter the position is "we did not put any assumptions about what the RVO would do to the curves or the profitability beyond what the curves are already showing." Stripping the policy upside from the base case is honest, but it also means any RVO disappointment now has no offsetting downside cushion — the guide reflects the worst-case assumption on biofuel policy.

The capital structure narrative continued its quiet deterioration. Q2 guided net interest expense at $220–250M; Q3 raised it to $380–400M; Q4 raises it again to $575–625M. Each quarter the post-Viterra cost has gotten heavier than the prior framing implied. D&A followed the same path: ~$490M → ~$710M → ~$975M. Management has stopped describing these as one-time normalization and now presents them as the new run-rate — which is the correct framing, but it confirms that the merger's near-term P&L impact was materially understated at close.

The aspirational language gap is wider than ever. "We've never been in a better position, we've never been more needed, and we've never been more prepared" — said in the same call that delivers a flat-to-slightly-down EPS guide, a Q1 called the lightest in a long time, and a WACC reduction from 7% to 6% paired with the assertion that long-term return expectations are unchanged. The cognitive dissonance is the story.